Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

15.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EpiATLAS - a reference for human epigenomic research.

bioRxiv : the preprint server for biology·2026
Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same author

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Blood cancer discovery·2026
Same author

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

HNRNPU mutations redirect cell cycle control to E2F in MYC-driven lymphomas.

Blood advances·2026
Same author

Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma.

Blood cancer discovery·2026

Related Experiment Video

Updated: Sep 28, 2025

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.7K

Harnessing Mitochondrial Mutations to ATAC Clonal Evolution in CLL.

Laura K Hilton1, David W Scott1,2

  • 1BC Cancer's Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada.

Cancer Discovery
|April 1, 2022
PubMed
Summary

Researchers tracked chronic lymphocytic leukemia (CLL) tumor evolution using single-cell sequencing. Mitochondrial DNA mutations revealed how cancer cell populations change under different selection pressures.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.8K

Related Experiment Videos

Last Updated: Sep 28, 2025

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

2.7K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.8K

Area of Science:

  • Oncology
  • Genomics
  • Epigenetics

Background:

  • Chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy.
  • Understanding tumor evolution is crucial for effective treatment strategies.

Discussion:

  • Penter and colleagues utilized combined assay for transposase-accessible chromatin using sequencing (scATAC-seq) and mitochondrial DNA sequencing (mtDNA-seq) in single cells.
  • This approach allowed for the tracking of individual tumor subclones within serial samples from CLL patients.
  • Naturally occurring mtDNA mutations served as barcodes to identify distinct cell lineages.

Key Insights:

  • Distinct chromatin accessibility profiles and copy-number alterations were observed in different subclones.
  • These profiles demonstrated unique patterns of tumor evolution.
  • The study highlights how varying selection pressures shape cancer progression.

Outlook:

  • This technology provides a powerful tool for dissecting clonal dynamics in leukemia.
  • Further application can elucidate mechanisms of treatment resistance and disease relapse.
  • Future studies can explore similar approaches in other hematological malignancies.